APPB - Applied Biosciences Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.7400
0.0000 (0.00%)
At close: 2:02PM EDT
Stock chart is not supported by your current browser
Previous Close0.7400
Open0.6500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7400 - 0.7400
52 Week Range0.4000 - 2.9500
Volume14
Avg. Volume1,901
Market Cap9.951M
Beta (3Y Monthly)0.07
PE Ratio (TTM)N/A
EPS (TTM)-0.2090
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE

    Applied BioSciences Appoints Judith Korner, M.D., Ph.D., as Inaugural Member of its Scientific Advisory Board for Applied BioPharma Division

    BEVERLY HILLS, CA / ACCESSWIRE / September 12, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today announced the appointment of Judith Korner, M.D., Ph.D., to its Scientific Advisory Board for the biopharma business unit of the Company, Applied BioPharma. “We are pleased to welcome Dr. Korner as a founding member of our Scientific Advisory Board.

  • ACCESSWIRE

    Applied BioSciences to Present at the Fall Investor Summit

    BEVERLY HILLS, CA / ACCESSWIRE / September 10, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today announced that Dr. Raymond Urbanski, Chief Executive Officer of Applied, will present at the Fall Investor Summit on Tuesday, September 17, 2019 at 10:00 AM ET in New York, NY. For more information about the conference, please click here to visit the conference website. A live audio webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company’s website.

  • ACCESSWIRE

    Applied BioSciences Subsidiary Enters into Contract for Services with Washington State Department of Agriculture

    BEVERLY HILLS, CA / ACCESSWIRE / August 27, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today announced that its majority owned subsidiary, Trace Analytics Inc., entered into a contract for services with the Washington State Department of Agriculture (WSDA) on July 24, 2019. This contract will include testing Industrial Hemp samples and include percentage testing for post-decarboxylation delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A).

  • Business Wire

    Applied BioSciences Reports First Quarter FY2020 Financial Results and Provides Corporate Update

    – Quarter marked by reinvigorated focus on purposefully built strategic business units leveraging science-driven cannabinoid research to address areas of significant unmet needs an

  • ACCESSWIRE

    The Stock Day Podcast Interviews Newly Appointed CEO of Applied BioSciences to Discuss Strategy to Propel Company to Next Phase of Growth

    PHOENIX, AZ / ACCESSWIRE / August 1, 2019 / The Stock Day Podcast announced the launch of a recent interview with Applied BioSciences Corp. (APPB) (“the Company”), a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics capabilities to its customers. CEO of the Company, Dr. Raymond Urbanski, joined Stock Day host Everett Jolly to discuss recent corporate advancements and the Company’s vision to build a world-class biopharmaceutical company and execute on its strategic initiatives to propel the Company to its next phase of growth.

  • ACCESSWIRE

    Applied BioSciences Provides Corporate Update and 2019 Business Outlook

    BEVERLY HILLS, CA / ACCESSWIRE / July 30, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today provided a corporate update and business outlook for the remainder of 2019.

  • Newsfile

    Applied BioSciences Announces Two Consecutive Quarters Posting Record Revenues for FY Ended March 2019

    Los Angeles, California--(Newsfile Corp. - July 24, 2019) - Applied BioSciences Corp. (OTCQB: APPB), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, as well as testing and analytics, and pet health industries, today announced that it has achieved a record revenue quarter with multiple milestones for the fiscal year ended March 31, 2019. The Company has continued to make strategic investments in ...

  • GlobeNewswire

    Applied BioSciences Launches Champ Organics CBD Product Line with Boxing Heavyweight Champion Shannon Briggs

    Applied Biosciences Corp. (OTC: APPB), a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, announced that has officially launched its Champ Organics product line with Shannon “the Cannon” Briggs, the former heavyweight boxing champion and world record-holder for the most first-round knockouts. The product line was created to formulate a line of athlete-focused cannabidiol (“CBD”) based health and wellness supplements to enhance training and recovery under the “Champ Organics” brand. The initial product launch includes CBD Isolate Infused MCT Soft Gels and Tinctures, Full Spectrum CBD Oil Infused Topicals and Nano CBD Infused Natural Beverage Shots and Spring Water.

  • GlobeNewswire

    Applied Biosciences Hires Former Pfizer Business Unit Chief Medical Officer as Chief Executive Officer

    Dr. Urbanski, will work closely with the Board of Directors, will set the vision and strategic direction of the company putting into place the organizational structure, processes and key hires necessary to continue the growth of Applied BioSciences.  Dr. Urbanski will also oversee the development of key products in the Applied BioSciences’ product pipeline, including assets within the newly formed Applied BioPharma division which is focused on innovative cannabinoid therapies being developed to address the unmet medical needs of patients across multiple therapeutic areas. Dr. Urbanski joins Applied BioSciences with an impressive list of accomplishments throughout his career ranging from academic research and private practice to his work and rise within the pharmaceutical industry.  Dr. Urbanski spent eight years with Pfizer and held several positions within the company which included medical director of diversified products, senior medical director of breast cancer products, senior medical director of oncology clinical R&D, and eventually Vice President/Chief Medical Officer of the Established Products Business Unit.  In addition to his roles with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of MannKind Corp., and Senior Director of US Medical Affairs for Aventis.

  • ACCESSWIRE

    Uptick Newswire Hosts Applied Biosciences Corp. on The Stock Day Podcast to Discuss The Expansion of Their CBD Product Lines

    PHOENIX, AZ / ACCESSWIRE / April 18, 2019 / Uptick Newswire Stock Day Podcast welcomed Applied Biosciences Corp. (APPB) (''the Company''), a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. Treasurer and Secretary, JJ Southard, joined Stock Day host Everett Jolly. Jolly began the interview by asking Southard to give listeners an update on the Company's current projects.

  • ACCESSWIRE

    Applied BioSciences Retains the Emmes Group to Partner on Therapeutic Development Initiatives

    LOS ANGELES, CA / ACCESSWIRE / April 8, 2019 / Applied Biosciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical, testing and pet health industries, announced that is has retained the Emmes Group to assist with the development and execution of the Company's partnership and technology licensing initiatives and strategies. Through this new partnership, Emmes and the Company will work together to formulate a line of medical and scientific focused cannabidiol ("CBD") based products to target the endocannabinoid system under the "Applied BioPharma" brand. Applied BioSciences has retained several industry leading individuals as scientific advisory board members and in corporate management consultative capacities.

  • GlobeNewswire

    Applied BioSciences Announces Partnership with Boxing Heavyweight Champion Shannon Briggs

    Through this new partnership, Briggs and the Company will work together to formulate a line of athlete-focused cannabidiol (“CBD”) based health and wellness supplements to enhance training and recovery under the “Champ Organics” brand. Additionally, Briggs and the Company will collaborate on an awareness campaign to help educate athletes around the world about the potential benefits of using CBD for pain management, relaxation, decreasing anxiety and improving sleep quality.  Briggs hopes to educate the public on the potential benefits of using CBD to help decrease dependence on opioids. “I have partnered with Applied BioSciences to develop and market Champ Organics because their products are made with the highest quality ingredients and all-natural CBD.  I am a firm believer in the benefits that CBD delivers for joint pain and headaches.

  • GlobeNewswire

    Applied BioSciences Announces Record Revenue

    Applied BioSciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical, testing and analytics and pet health industries, announced that it has achieved a record revenue quarter with multiple milestones. The company has made strategic investments in select brands and companies believed to be innovators in the consumer space.  The investment remains on the balance sheet under Equity Investments, but the company has begun a strategic review of options for the remaining equity stake.

  • GlobeNewswire

    Applied BioSciences Receives Distribution from Investment in JUUL

    LOS ANGELES, Feb. 05, 2019 -- Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health.

  • GlobeNewswire

    Applied BioSciences Expands Scientific Advisory Board

    Applied BioSciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that Dr. Xiang-Qun (Sean) Xie has joined its Scientific Advisory Board. The company continues to add professionals who are expert in relevant fields, such as scientific research and development, FDA procedures and medicine.  These professionals will provide the company with an outstanding base of knowledge and experience to build on and advance the development of additional products.  With the addition of several prominent scientists and physicians and their knowledge base, clinical trials, product development, and design procedures for submitting products to the FDA can be done in an expedited time frame.

  • GlobeNewswire

    Applied BioSciences Acquires Majority Stake in Cannabis Testing Firm

    Applied Biosciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that it has acquired a majority stake in Trace Analytics, Inc., a leading testing and analytics company. Although the health benefits of Cannabis and CBD are becoming well known, one of the challenges is the safety and testing of these products which are ingested, vaped and applied topically.  Many products in the market are cheaply-made, with multiple toxins, chemicals and synthetics.   Some of the products include high levels of THC, harmful substances, illegally processed synthetic cannabinoids, and even some that have no CBD at all. Applied Biosciences intends to position Trace as the leading provider of testing solutions for both compliance requirements and consumer safety.

  • GlobeNewswire

    Applied BioSciences Withdraws Equity Offering after Passing of Farm Bill

    Applied BioSciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that it has withdrawn its Registration Statement filed on December 3, 2018 and will not sell any securities under the Common Stock Purchase Agreement related to the Registration Statement. On December 20, 2018, President Trump signed the US Farm Bill into law. The new law defines hemp as an agricultural product for the first time in 50 years and allows American farmers to plant and harvest hemp.

  • ACCESSWIRE

    Applied BioSciences to Present at the 11th Annual LD Micro Main Event

    LOS ANGELES, CA / ACCESSWIRE / November 27, 2018 / Applied BioSciences Corp., a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that it will be presenting at the 11th Annual LD Micro Main Event on December 4th at 5:30pm PST. The LD Micro Main Event will take place December 4th, 5th, and 6th, in Los Angeles at the Luxe Sunset Bel Air Hotel, will feature 250 companies, and will be attended by over 1,200 individuals. Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry.

  • ACCESSWIRE

    Uptick Newswire interviews Applied BioSciences for The First time on the Stock Day Radio podcast and Discuses the Growth of Their CBD Product Lines

    LOS ANGELES, CA / ACCESSWIRE / November 26, 2018 / Applied BioSciences Corp. (APPB) is a diversified cannabinoid therapeutics company that specializes in the medical,bioceutical, and pet health industries. The President of Applied BioSciences, Chris Bridges, joined Stock Day's Everett Jolly for the first time to discuss the Company's newly expanded product line, as well as their goals for growth going forward. Jolly began the interview by asking Bridges for a little bit of background information on the Company, as well as himself.

  • ACCESSWIRE

    Applied BioSciences Enters the Vape Inhaler Market

    LOS ANGELES, CA / ACCESSWIRE / November 7, 2018 / Applied BioSciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical,bioceutical and pet health industries, announced that it has expanded its product line and launched an alternative vape inhaler technology using water vapor and natural flavors. The Remedi Plus Therapeutic Vapor Inhaler contains a revolutionary recipe of steam-distilled essential oils and flower essences uniquely blended with CBD Isolate. The Remedi Plus product line has been crafted with just simple flavored waters by nature and blended with CBD in vapor form.

  • GlobeNewswire

    Applied BioSciences Enters into $1 Million Equity Financing Agreement with Triton Funds

    Applied BioSciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that it has entered into a Common Stock Purchase Agreement with Triton Funds, LP, a Delaware limited partnership (“Triton Funds”), in which Triton Funds has agreed to purchase up to $1,000,000 of registered common stock of the Company in connection with a separate Registration Rights Agreement. It's beneficial for everyone, especially our shareholders who will benefit by the significant investment Triton Funds is making in our company,” stated Chris Bridges, President. “At Triton Funds we dive in and invest in companies that make a positive impact in evolving spaces, such as the CBD industry.